ArticleJournal of family medicine and primary care2025
Meta-analysis on clinical manifestation and laboratory parameters of COVID-19-associated multisystem inflammatory syndrome in children (MIS-C).
Article in Journal of family medicine and primary care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: We aimed to systematically identify clinical manifestations and lab parameters of COVID-19-associated multisystem inflammatory syndrome in children (MIS-C). Methods: We searched from Google Scholar, PubMed, and Cochrane Library with the Medical Subject Heading (MeSH) key, which includes information about clinical characteristics and severity of patient's illness. We analyzed the clinical characteristics and lab parameters of MIS-C. Results: We identified a total of 44 eligible studies, including 1840 patients with COVID-19-associated MIS-C. Most common features were abdominal pain 74% (0.67,0.81), shock 72% (0.56,0.86), vomiting 69% (0.60,0.78), diarrhea 62% (0.53,0.72), rashes 60% (0.55,0.65), conjunctival infection 52% (0.44,0.60), others include myocarditis 49% (0.27,0.71), complete Kawasaki presentation 44% (0.23,0.66), respiratory distress 43% (0.16,0.73), oral mucosal changes 40% (0.31,0.49). Conclusion: The results of this review show that SARS-CoV-2-associated MIS-C can present with multisystem involvement and can show an increase in inflammatory markers. MIS-C can have presentationslike Kawasaki disease, which needs high index of suspicion to diagnose MIS-C. Clinical features and lab parameters help in early diagnosis and prompt treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.